Palatin Technologies (PTN) Total Current Liabilities (2011 - 2026)
Palatin Technologies' (PTN) quarterly Total Current Liabilities came in at $2.5 million in Q1 2026, down 74.76% YoY from $10.0 million in Q1 2025, and down 59.95% on a QoQ basis from $6.3 million in Q4 2025.
Palatin Technologies (PTN) Total Current Liabilities (2011 - 2026) Analysis & Trends
Palatin Technologies (PTN) has 15 years of Total Current Liabilities data on file, last reported at $2.5 million in Q1 2026.
- Quarterly Total Current Liabilities fell 74.76% year-over-year to $2.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.5 million (down 74.76% YoY) and the FY2025 annual result came in at $8.0 million, down 17.06% from the prior year.
- Total Current Liabilities fell to $2.5 million in Q1 2026, from $6.3 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $16.3 million in Q2 2022 to a low of $2.5 million in Q1 2026.
- A 5-year average of $10.6 million and a median of $10.0 million in 2025 frame the typical range for Total Current Liabilities.
- Annual changes were most pronounced in 2022 — Total Current Liabilities surged 62.05% — and 2026, when it slumped 74.76%.
- Tracing PTN's Total Current Liabilities over 5 years: stood at $11.4 million in 2022, then dropped by 1.93% to $11.2 million in 2023, then declined by 14.65% to $9.6 million in 2024, then tumbled by 33.75% to $6.3 million in 2025, then plunged by 59.95% to $2.5 million in 2026.
- The last three Total Current Liabilities figures came in at $2.5 million (Q1 2026), $6.3 million (Q4 2025), and $8.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.66 Bn | 131.81 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 86.52 Bn | 78.52 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 65.30 Bn | 60.11 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 59.18 Bn | 54.04 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 42.08 Bn | 36.98 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 31.77 Bn | 28.46 Bn | 992.69 Mn | 1.51 Bn |
| 7 | BioNTech SE | 28.13 Bn | 9.74 Bn | 668.28 Mn | 2.49 Bn |
| 8 | Insmed | 27.51 Bn | 26.35 Bn | 358.27 Mn | 438.74 Mn |
| 9 | Royalty Pharma | 27.16 Bn | 26.32 Bn | - | 630.93 Mn |
| 10 | Palatin Technologies | 39.40 Mn | 39.40 Mn | - | 2.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.54 Mn |
| Dec 31, 2025 | 6.33 Mn |
| Sep 30, 2025 | 8.22 Mn |
| Jun 30, 2025 | 8.01 Mn |
| Mar 31, 2025 | 10.05 Mn |
| Dec 31, 2024 | 9.56 Mn |
| Sep 30, 2024 | 9.86 Mn |
| Jun 30, 2024 | 9.66 Mn |
| Mar 31, 2024 | 8.53 Mn |
| Dec 31, 2023 | 11.20 Mn |
| Sep 30, 2023 | 13.61 Mn |
| Jun 30, 2023 | 15.13 Mn |
| Mar 31, 2023 | 11.85 Mn |
| Dec 31, 2022 | 11.42 Mn |
| Sep 30, 2022 | 15.86 Mn |
| Jun 30, 2022 | 16.26 Mn |
| Mar 31, 2022 | 11.98 Mn |
| Dec 31, 2021 | 13.86 Mn |
| Sep 30, 2021 | 9.79 Mn |
| Jun 30, 2021 | 10.51 Mn |